#United States #Canton #Kelyniam Global #Fusion Implant #Cranial Prosthetics

Kelyniam Global Reports Strong Financial Results for 2025

Kelyniam Global (OTC: KLYG), specializing in custom cranial implants, recently released its financial outcomes for the fiscal year ending December 31, 2025. The results highlight a remarkable recovery in the second half of the year, showcasing the company's resilience and operational efficiency despite earlier challenges.

CEO Ross Bjella emphasized the strong rebound, stating, "Our team delivered a solid performance in the latter half while making meaningful progress in bottom-line improvements through effective expense management." The company achieved an impressive 85% reduction in net loss, a testament to the strength of its core business model and an enhanced product lineup.

Financial Highlights

The 2025 financial figures revealed a total revenue of $3,053,222, marking an 8% decline from $3,328,384 in the previous year. However, the company experienced a noteworthy recovery towards the year's end.

• - Gross profit fell slightly to $2,387,283 from $2,594,137.
• - The operating loss was recorded at $(96,449), a shift from an operating income of $277,037 in 2024.
• - The net loss stood at $(138,555), reflecting an 85% improvement from $(920,206) in the prior year.
• - EBITDA decreased to $(81,661), down from $322,824.

These results signify Kelyniam's stable core business, emphasizing effective adaptations to fluctuating market dynamics.

Innovative Product Launches

Among the significant achievements, Kelyniam secured FDA 510(k) clearance for its Fusion™ cranial and craniofacial implants. These groundbreaking implants utilize the innovative VESTAKEEP® Fusion, a biomaterial that unites PEEK with biphasic calcium phosphate (BCP). This advanced material is engineered to maximize advantages such as biocompatibility and robust mechanical integrity.

The Fusion™ implants are designed with Kelyniam's exclusive integrated fixation system, enabling rapid delivery within 24-48 hours. This agility is crucial for surgical applications and enhances patient care by ensuring timely access to needed prosthetics.

Strategic Future Focus

In late 2025, Kelyniam received an unsolicited acquisition proposal from a third party. However, after careful evaluation, the board deemed the offer significantly undervalued the company's intrinsic assets and its long-term potential. Consequently, the company decided not to pursue discussions at that time, underlining their commitment to maximizing shareholder value by exploring better-suited opportunities.

Kelyniam Global remains dedicated to strengthening its market position and furthering innovation within the cranial surgery space. By continuously assessing its strategies and growth avenues, the company looks set to solidify its reputation as a leader in the custom cranial implant sector.

Conclusion

Kelyniam Global's performance in 2025 illustrates its adaptability and potential for future growth. The developments in product innovation, particularly the Fusion™ implants, present exciting opportunities for both the company and its stakeholders. As Kelyniam continues on this upward trajectory, its strategic decisions will likely enhance its market presence while improving health outcomes for patients in need of cranial reconstruction. To learn more about Kelyniam Global and its offerings, visit www.Kelyniam.com.